Central nervous system drug evaluation using positron emission tomography

Clinical Psychopharmacology and Neuroscience

Volumn 9, Issue 1, 2011, Pages 9-16

  Sekine, Mizuho ^a,b   Maeda, Jun ^a   Shimada, Hitoshi ^a   Nogami, Tsuyoshi ^a,b   Arakawa, Ryosuke ^a,b   Takano, Harumasa ^a   Higuchi, Makoto ^a   Ito, Hiroshi ^a   Okubo, Yoshiro ^b   Suhara, Tetsuya ^a  

^a NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES   (Japan)

^b NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

micro PET; Norepinephrine transporter; Occupancy; Positron emission tomography; Serotonin transporter

Indexed keywords

ARIPIPRAZOLE; CENTRAL NERVOUS SYSTEM AGENTS; CLOMIPRAMINE; CLOZAPINE; DOPAMINE 2 RECEPTOR; DULOXETINE; EPIDEPRIDE; FLUVOXAMINE; NEUROLEPTIC AGENT; NORADRENALIN TRANSPORTER; OLANZAPINE; PALIPERIDONE; RACLOPRIDE C 11; RISPERIDONE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR; SULPIRIDE; SULTOPRIDE; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; YKP 1358;

ALZHEIMER DISEASE; DEPRESSION; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG PROTEIN BINDING; HUMAN; HYPOPHYSIS; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; REVIEW; SCHIZOPHRENIA;

EID: 79955763846     PISSN: 17381088     EISSN: None     Source Type: Journal    
DOI: 10.9758/cpn.2011.9.1.9     Document Type: Review

References (50)

1. Wong DF, Potter WZ, Brasic JR. Proof of concept: functional models for drug development in humans. In: Davis KL, ed. Neuropsychopharmacology: The Fifth Generation of Progress: Lippincott Williams & Wilkins; 2002. p.457-473.
2. Seeman P, Lee T. Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons. Science 1975;188:1217-1219.
3. 2 dopamine receptor binding in the living human brain by PET. Science 1986;231:258-261.
4. 2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatry 1992;49:538-544.
5. 2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients. Biol Psychiatry 1993;33:227-235.
6. Kapur S, Zipursky R, Jones C, Remington G, Houle S. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry 2000;157:514-520.
7. 2 and 5-HT2A receptor occupancy in schizophrenic patients. Am J Psychiatry 1999;156:869-875.
8. 2-dopamine receptor occupancy with risperidone. Psychopharmacology (Berl) 2001;154:112-114.
9. Arakawa R, Ito H, Okumura M, Takano A, Takahashi H, Takano H, et al. Extrastriatal dopamine D(2) receptor occupancy in olanzapine-treated patients with schizophrenia. Eur Arch Psychiatry Clin Neurosci 2010;260:345-350.
10. 2 receptor occupancy of olanzapine in schizophrenia: a PET investigation. Am J Psychiatry 1998;155:921-928.
11. 2 receptor occupancy in patients with schizophrenia. Psychopharmacology (Berl) 2008;197:229-235.
12. 2 receptor occupancy-plasma concentration relationships with a novel antipsychotic, YKP1358, using serial PET scans in healthy volunteers. Clin Pharmacol Ther 2007;81:252-258.
13. Takano A, Suhara T, Yasuno F, Suzuki K, Takahashi H, Morimoto T, et al. The antipsychotic sultopride is overdosed - a PET study of drug-induced receptor occupancy in comparison with sulpiride. Int J Neuropsychopharmacol 2006;9:539-545.
14. Yokoi F, Grunder G, Biziere K, Stephane M, Dogan AS, Dannals RF, et al. Dopamine D-2 and D-3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [C-11]raclopride. Neuropsychopharmacology 2002;27:248-259.
15. Grunder G, Carlsson A, Wong DF. Mechanism of new antipsychotic medications: occupancy is not just antagonism. Arch Gen Psychiatry 2003;60:974-977.
16. 3 receptor-binding profile of clozapine in patients with schizophrenia. Neuropsychopharmacology 2006;31:1027-1035.
17. 2 receptor occupancy in living human brain from plasma pharmacokinetics of antipsychotics. Int J Neuropsychopharmacol 2004;7:19-26.
18. Pilowsky LS, Mulligan RS, Acton PD, Ell PJ, Costa DC, Kerwin RW. Limbic selectivity of clozapine. Lancet 1997;350:490-491.
19. 3 receptor occupancy by risperidone: a [123I]-epidepride SPET study. J Clin Psychopharmacol 2003;23:5-14.
20. Xiberas X, Martinot JL, Mallet L, Artiges E, Loc'H C, Mazière B, et al. Extrastriatal and striatal D(2) dopamine receptor blockade with haloperidol or new antipsychotic drugs in patients with schizophrenia. Br J Psychiatry 2001;179:503-508.
21. 2 receptor occupancy by the second-generation antipsychotic drug risperidone in humans: a positron emission tomography study. Int J Neuropsychopharmacol 2009;12:667-675.
22. 2 receptor occupancy in antipsychotic drug-treated patients. J Clin Psychopharmacol 1998;18:305-310.
23. 3 dopamine receptor occupancy in amisulpride treated patients. Psychopharmacology (Berl) 2004;175:367-373.
24. 2 receptor occupancy in the pituitary and cerebral cortex: relation to antipsychotic-induced hyperprolactinemia. J Clin Psychiatry 2010;71:1131-1137.
25. Meyer JH, Wilson AA, Sagrati S, Hussey D, Carella A, Potter WZ, et al. Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study. Am J Psychiatry 2004;161:826-835.
26. Suhara T, Takano A, Sudo Y, Ichimiya T, Inoue M, Yasuno F, et al. High levels of serotonin transporter occupancy with low-dose clomipramine in comparative occupancy study with fluvoxamine using positron emission tomography. Arch Gen Psychiatry 2003;60:386-391.
27. Takano A, Suzuki K, Kosaka J, Ota M, Nozaki S, Ikoma Y, et al. A dose-finding study of duloxetine based on serotonin transporter occupancy. Psychopharmacology (Berl) 2006;185:395-399.
28. Martin AJ, Tebbs VM, Ashford JJ. Affective disorders in general practice. Treatment of 6000 patients with fluvoxamine. Pharmatherapeutica 1987;5:40-49.
29. Stokes PE. Fluoxetine: a five-year review. Clin Ther 1993;15:216-243.
30. Papakostas GI, Thase ME, Fava M, Nelson JC, Shelton RC. Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents. Biol Psychiatry 2007;62:1217-1227.
31. Thase ME, Pritchett YL, Ossanna MJ, Swindle RW, Xu J, Detke MJ. Efficacy of duloxetine and selective serotonin reuptake inhibitors: comparisons as assessed by remission rates in patients with major depressive disorder. J Clin Psychopharmacol 2007;27:672-676.
32. Schou M, Halldin C, Sóvágó J, Pike VW, Hall H, Gulyás B, et al. PET evaluation of novel radiofluorinated reboxetine analogs as norepinephrine transporter probes in the monkey brain. Synapse 2004;53:57-67.
33. 2. J Nucl Med 2008;49:1270-1276.
34. 2. Eur J Nucl Med Mol Imaging 2008;35:153-157.
35. 2. Neuroimage 2008;42:474-482.
36. 2. Psychopharmacology (Berl) 2010;210:331-336.
37. Kudo Y. Development of amyloid imaging PET probes for an early diagnosis of Alzheimer's disease. Minim Invasive Ther Allied Technol 2006;15:209-213.
38. Kudo Y, Okamura N, Furumoto S, Tashiro M, Furukawa K, Maruyama M, et al. 2-(2-[2-Dimethylaminothiazol-5-yl]ethenyl)-6- (2-[fluoro]ethoxy)benzoxazole: a novel PET agent for in vivo detection of dense amyloid plaques in Alzheimer's disease patients. J Nucl Med 2007;48:553-561.
39. 2184. Eur J Nucl Med Mol Imaging 2009;36:1859-1863.
40. Choi SR, Golding G, Zhuang Z, Zhang W, Lim N, Hefti F, et al. Preclinical properties of 18F-AV-45: a PET agent for Abeta plaques in the brain. J Nucl Med 2009;50:1887-1894.
41. Wong DF, Rosenberg PB, Zhou Y, Kumar A, Raymont V, Ravert HT, et al. In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18). J Nucl Med 2010;51:913-920.
42. Rinne JO, Brooks DJ, Rossor MN, Fox NC, Bullock R, Klunk WE, et al. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol 2010;9:363-372.
43. Ota T, Shinotoh H, Fukushi K, Kikuchi T, Sato K, Tanaka N, et al. Estimation of plasma IC50 of donepezil for cerebral acetylcholinesterase inhibition in patients with Alzheimer disease using positron emission tomography. Clin Neuropharmacol 2010;33:74-78.
44. Maeda J, Ji B, Irie T, Tomiyama T, Maruyama M, Okauchi T, et al. Longitudinal, quantitative assessment of amyloid, neuroinflammation, and anti-amyloid treatment in a living mouse model of Alzheimer's disease enabled by positron emission tomography. J Neurosci 2007;27:10957-10968.
45. Saijo T, Maeda J, Okauchi T, Maeda J, Morio Y, Kuwahara Y, et al. Utility of small-animal positron emission tomographic imaging of rats for preclinical development of drugs acting on the serotonin transporter. Int J Neuropsychopharmacol 2009;12:1021-1032.
46. Maeda J, Morino Y, Katayama J, Horie S, Inaba K, Nishiyama A, et al. p.2.d.002 Wf-516, a novel antidepressant with dual serotonergic activity: II. Pharmacological profiles ex vivo and in vivo to monoamine transporters in comparison with standard antidepressant. Eur Neuropsychopharmacol 2006;16:333-334.
47. Takano A, Suhara T, Ichimiya T, Yasuno F, Suzuki K. Time course of in vivo 5-HTT transporter occupancy by fluvoxamine. J Clin Psychopharmacol 2006;26:188-191.
48. Tai YC, Ruangma A, Rowland D, Siegel S, Newport DF, Chow PL, et al. Performance evaluation of the microPET focus: a third-generation microPET scanner dedicated to animal imaging. J Nucl Med 2005;46:455-463.
49. Hildebrandt IJ, Su H, Weber WA. Anesthesia and other considerations for in vivo imaging of small animals. ILAR J 2008;49:17-26.
50. Tokugawa J, Ravasi L, Nakayama T, Lang L, Schmidt KC, Seidel J, et al. Distribution of the 5-HT(1A) receptor antagonist [(18)F]FPWAY in blood and brain of the rat with and without isoflurane anesthesia. Eur J Nucl Med Mol Imaging 2007;34:259-266.